Thermo Fisher launches CHO cell line development kit for biologics manufacturing
Thermo Fisher Scientific, a life sciences tools and services company headquartered in Waltham, Massachusetts, has launched the Gibco CHOvantage GS cell line development kit, a Chinese hamster ovary (CHO)-based platform reportedly designed to compress development timelines and improve process consistency for biologics and biosimilar manufacturers.
According to the company, the kit enables researchers to achieve protein titers of 7 g/L or more in fed-batch cultures, establish stable pools in as little as four weeks, and select stable clones within 14 weeks. The platform integrates a transposon-based vector system with Thermo Fisher’s Efficient-Pro media and feeds, and is intended to simplify technology transfer and support the transition from development to commercial manufacturing.
The kit includes research-use rights with purchase and offers royalty-free, clinical-stage licensing options meant to improve cost predictability and reduce barriers to market compared with cell line development systems that require milestone payments during clinical development.
Sara Henneman, vice president and general manager of Thermo Fisher’s cell culture and cell therapy business, said in a statement the platform is intended to help customers compress development timelines, increase confidence in quality, and lower overall costs.
Andy Campbell, senior director of research and development at Thermo Fisher, said in a statement the harmonized workflow is designed to simplify tech transfer and enable a smoother transition from development to manufacturing.
The launch follows a series of recent manufacturing investments by Thermo Fisher. Last week, the company announced a collaboration with SHL Medical to integrate autoinjector assembly with sterile fill-finish and commercial packaging at its Ridgefield, New Jersey site, which was acquired from Sanofi in 2025.
The company has also committed $2 billion to U.S. manufacturing and R&D over four years, with $1.5 billion earmarked for capital expenditures, and is expanding sterile fill-finish capacity across sites in Greenville, North Carolina; Allentown, Pennsylvania; Horsham, UK; Ferentino, Italy and the Asia-Pacific region.